Telday-40/Telday-80

Monotherapy or in combination w/ other antihypertensive agents for the treatment of HTN.

HTN Individualized dose. Initially 40 mg once daily. BP response is dose-related over range of 20-80 mg. Mild to moderate hepatic impairment Max: 40 mg once daily. Consider lower doses in patient w/ hepatic impairment.

May be taken with or without food.

Hypersensitivity. Patients w/ biliary obstructive disorder & severe hepatic impairment. Do not co-administer w/ aliskiren in patients w/ diabetes. Pregnancy (2nd & 3rd trimester) & lactation.

Correct symptomatic hypotension in vol- or salt-depleted patients (eg, those being treated w/ high doses of diuretics). Hyperkalemia may occur particularly in patients w/ advanced renal impairment, heart failure, on renal replacement therapy, on K supplements, K-sparing diuretics, K-containing salt substitutes or other drugs that increase K levels. Patients w/ biliary obstructive disorders or hepatic insufficiency, severe CHF or renal dysfunction, unilateral or bilateral renal artery stenosis. Avoid combined use of renin-angiotensin aldosterone system inhibitors. Concomitant use w/ ramipril is not recommended. Monitor BP, renal function & electrolytes. Do not co-administer w/ aliskiren in patients w/ diabetes; avoid use w/ aliskiren in patients w/ renal impairment (GFR <60 mL/min/1.73 m²). Not recommended in patients w/ primary aldosteronism. Caution in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy. Consider periodic determinations of serum electrolytes to detect possible electrolyte imbalances. Discontinue as soon as pregnancy is detected. Can cause fetal & neonatal morbidity & death when administered to pregnant women. Discontinue treatment if oligohydramnios is observed unless considered life-saving for the mother. Discontinue nursing or discontinue therapy; considering importance of the drug to the mother. Neonates w/ history of in utero exposure to telmisartan.

Renal dysfunction upon use w/ ramipril. Headache, dizziness, asthenia, coughing, nausea, fatigue, weakness, edema, face edema, lower limb edema, angioneurotic edema, urticaria, hypersensitivity, increased sweating, erythema, chest pain, atrial fibrillation, CHF, MI, increased BP, aggravated HTN, hypotension (including postural hypotension), hyperkalemia, syncope, dyspepsia, diarrhea, pain, UTI, erectile dysfunction, back pain, abdominal pain, muscle cramps (including leg cramps), myalgia, bradycardia, eosinophilia, thrombocytopenia, increased uric acid, abnormal hepatic function/liver disorder, renal impairment including acute renal failure, anemia, increased CPK, anaphylactic reaction, tendon pain (including tendonitis, tenosynovitis), drug eruption (toxic skin eruption mostly reported as toxicoderma, rash & urticaria), hypoglycemia (in diabetic patients), & angioedema (w/ fatal outcome).

Do not co-administer w/ aliskiren in patients w/ diabetes or renal impairment (GFR <60 mL/min). May increase digoxin peak plasma conc & trough conc. Reversible increases in serum lithium conc & toxicity. May result in deterioration of renal function including possible acute renal failure in patients who are elderly, vol-depleted (including those on diuretic therapy) or w/ compromised renal function w/ NSAIDs including selective COX-2 inhibitors. Antihypertensive effect may be attenuated by NSAIDs including selective COX-2 inhibitors. Possible additive pharmacodynamic effects w/ ramipril & ramiprilat.

Angiotensin II Antagonists

C09CA07 - telmisartan ; Belongs to the class of angiotensin II receptor blockers (ARBs). Used in the treatment of cardiovascular disease.

Rx